It is rumored that Li Zekai's Yingke Development plans to sell a majority stake in Berry Investment
On February 1, according to market sources, PCCW Chairman and FWD Group founder Li Zekai's Yingke Development plans to sell a majority stake in asset management company Berry Investment, and Yingke Development has hired JPMorgan Chase to handle the sale and has started preliminary negotiations with a number of financial institutions. At present, Pacific Century Development, JPMorgan Chase and Berry have not responded. According to the data, 60% of Pinebridge Investment's investment portfolio is located in the Asia-Pacific region, but rising interest rates and geopolitical tensions have affected asset prices in the region. As of the end of September 2023, P&R Investment managed approximately 25% of FWD Group's assets. Berry recorded a loss of $78 million in 2022 and a profit of $15 million in 2021. According to Berry's website, as of the end of 2023, Berry's assets under management (AUM) worldwide were US$157.1 billion (about HK$1.23 trillion) in assets. Pinebridge currently has more than 700 employees in 25 offices around the world, including 230 investment specialists.
The clinical application for semaglutide weight loss indication of Hanyu Pharmaceutical was accepted
On the evening of February 1, Hanyu Pharmaceutical announced that the company received the "Notice of Acceptance" approved and issued by the State Food and Drug Administration for the clinical trial application of semaglutide injection, and the indication of the drug is "as an adjunct treatment to low-calorie diet and increased physical activity for weight management in adult patients who are obese or overweight and have at least one weight-related comorbidity." Hanyu Pharmaceutical said that after semaglutide injection received the application for new drug clinical trial from the State Food and Drug Administration, it will be transferred to the Center for Drug Evaluation of the State Food and Drug Administration for review and approval, and the clinical trial approval notice can be obtained before the clinical trial can be carried out. Semaglutide is a GLP-1 agonist, and the original manufacturer is Novo Nordisk, which has become a phenomenal single product in the pharmaceutical field in 2023 due to its application in the field of hypoglycemic and weight loss. According to the 2023 results recently released by Novo Nordisk, semaglutide achieved a total of 145.811 billion Danish kroner (21.201 billion US dollars) in sales, a year-on-year increase of 88.78%, accounting for 62.78% of total revenue.
China South City intends to sell approximately 30.6% of the equity interest in Xi'an China South City through public bidding
On February 1, China South City announced that China South City intends to sell about 30.6472% of the equity of Xi'an China South City Co., Ltd. (hereinafter referred to as "Xi'an China South City") through public bidding (which can be adjusted to 38.6988%). The tender notice was published on the website of China South City on 1 February 2024 and will expire on 6 February 2024. According to the investigation, Xi'an China South City indirectly holds 30.6472% of the equity of China South City, which is recorded as an associate company in the financial statements of China South City. Xi'an China South City is mainly engaged in the development and operation of integrated trade logistics and commodity trading centers, and participated in China South City's project in Xi'an (i.e. Xi'an South China City), but did not participate in the other seven projects of China South City in Chinese mainland. Xi'an South China City is located in Xi'an International Port Area, has been put into operation, the commodity trading center covers the business formats including hardware and electromechanical, curtain fabric, textile and garment, leather and fur, automobile and motorcycle auto parts, home building materials, 1668 New Times Square, outlets, cross-border e-commerce, Central Asia and ASEAN product exhibition center, etc., of which the 1668 New Times Square project was included in the key projects of Shaanxi Province in 2019 and 2020.
Kowloon Development plans to sell a 60% stake in a land parcel in Yangpu District, Shanghai for HK$1.39 billion
On February 1, Kowloon Development announced that Future Star International Limited, a direct wholly-owned subsidiary of Kowloon Development, entered into an agreement with the buyer, Polytec Holdings International Limited, in relation to the sale. Accordingly, Kowloon Development intends to sell 60% of the share capital of Wei On Limited (hereinafter referred to as "Wei An") for HK$1.392 billion. Upon completion, the Target Company will be 60% owned by the Purchaser and the Vendor respectively, the Target Company and its subsidiaries will cease to be subsidiaries of the Company, and the financial results of the Target Group will no longer be consolidated into the Company's consolidated financial statements, but will be recorded in the Company's consolidated financial statements using the equity method. The buyer, Polytec Holdings International Limited, is principally engaged in investment holding business and is ultimately wholly owned by Mr. Ke (Executive Director and Controlling Shareholder of Kowloon Development). It is reported that the target company indirectly owns the land located in Yangpu District, Shanghai, the PRC and designated for residential, commercial and office purposes. A building permit has been obtained for the development of the site, and foundation works are expected to commence in the first quarter of 2024.
Dongpeng Beverage completed the re-election of the board of directors and the new commander led the development of the national strategy
On the evening of February 1, Dongpeng Beverage disclosed the "Announcement on the Completion of the General Election of the Board of Directors and the Board of Supervisors and the Appointment of Senior Managers", officially completing the matters related to the general election of the Board of Directors and the Board of Supervisors, and achieving a smooth succession. The third session of the board of directors of the company is led by Mr. Lin Muqin, chairman of the board, including six non-independent directors: Lin Muqin, Lin Mugang, Jiang Weiwei, Lu Yifu, Zhang Lei, and Lin Daiji, employee representative director, and three independent directors: You Xiao, Li Hongbin and Zhao Yali. The Board of Supervisors is led by Mr. Yu Bin, Chairman of the Board of Supervisors, and its members include Yu Bin, Hu Yajun and employee representative supervisor Li Xueli, who are responsible for the supervision and management of the Company. In addition, the appointment of senior management shows that Mr. Lin Muqin is also the president, Mr. Lin Mugang is the executive president, Lu Yifu, Jiang Weiwei and Zhang Lei are appointed as vice presidents, Zhang Lei is also the secretary of the board of directors, and Mr. Peng Dexin is the chief financial officer.
Liang Donghai, deputy mayor of Yunfu City, and his party visited Kangzhi Pharmaceutical
Recently, Liang Donghai, deputy mayor of Yunfu Municipal People's Government of Guangdong Province, and his delegation visited Kangzhi Pharmaceutical. Hong Jiangtao, President of Kangzhi Pharmaceutical, was warmly received, and Gong Junjian, General Manager of the Strategic Development Department, accompanied by leaders to visit and participate in the discussion and exchange. The delegation first came to the Kangzhi corporate culture exhibition hall to learn more about the development history, main business, market layout and other information of Kangzhi Pharmaceutical, and visited the secretariat of the "Modern Industry College of Traditional Chinese Medicine of Guangdong Pharmaceutical University" jointly initiated by Kangzhi Pharmaceutical, Yunfu Municipal Government, Guangdong Pharmaceutical University and other parties to understand the working mechanism of the secretariat. During the visit, the leaders of the Yunfu delegation highly appreciated the overall strength of Kangzhi Pharmaceutical.
Another innovative drug from Sino Biopharma is to be included in the priority review
On January 31, according to the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the new indication of PD-L1 monoclonal antibody TQB2450 injection (bemosubalimab) of Chia Tai Tianqing Pharmaceutical Group, a subsidiary of China Biopharmaceutical, a leading Hong Kong pharmaceutical company, is proposed to be included in the priority review and approval procedure for the treatment of patients previously received by Anlotinib hydrochloride capsules. Patients with recurrent or metastatic endometrial cancer who have failed or are intolerant of second-line chemotherapy regimens and who are not microsatellite unstable (non-MSI-H) or non-DNA mismatch repair deficient (non-dMMR). It is understood that bemosumumab (TQB2450) is an innovative fully humanized anti-PD-L1 monoclonal antibody with a new sequence independently developed by CTTQ. In April 2022, bemosubimab in combination with anlotinib for the treatment of recurrent or metastatic endometrial cancer was granted Breakthrough Therapy Designation by the CDE, and in January 2023, bemosubasumab was first declared for marketing in China for the first-line treatment of small cell lung cancer in combination with anlotinib. Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor developed by CT Tianqing, which has been approved for five indications, including advanced non-small cell lung cancer and small cell lung cancer, since 2018.
Tencent led the formulation of the world's first international standard for in-vehicle mini programs
In January 2024, the Standards Authority of the International Telecommunication Union (ITU-T) officially released the international standard for the framework and technical requirements of in-vehicle multimedia applets led by Tencent. It is reported that this is the world's first international standard for on-board applets led by Chinese enterprises, aiming to provide technical guidelines for the global on-board applet application framework, and provide solutions for equipment interconnection, data exchange and service sharing in the automotive industry, marking the international recognition of the technical practice of mainland technology enterprises in the field of on-board application ecology.
In 2024, the imported online game version will be released, and Tencent's two Switch games will pass the review
On February 2, the National Press and Publication Administration announced the approval information for imported online games in 2024, with a total of 32 games passing the review, including a number of mobile games and console games. Silver Persimmon Finance noticed that Tencent (00700. HK) won the titles of two Nintendo Switch games, including Kirby Nova Alliance and Taiko no Tatsujin, but both games were released in 2018 and are not new.